Ketamine and PTSD: What Brain Research Can Tell Us

Questions about ketamine and PTSD often begin with brain chemistry: glutamate, NMDA receptors, or neuroplasticity. Those terms describe areas of research. They do not establish that ketamine reliably treats PTSD, repairs trauma, or gives someone a predictable “reset.”

The current VA/DoD PTSD guideline suggests against ketamine for PTSD. A discussion of possible mechanisms should keep that clinical recommendation visible. Patients should hear about established treatment options before being asked to draw conclusions from laboratory findings.

Compounded ketamine is not FDA-approved. FDA has not reviewed compounded medications for safety, effectiveness, or quality before marketing. Ketamine injection is approved for anesthesia, not psychiatric disorders. Compounded ketamine nasal spray is different from Spravato, the FDA-approved esketamine product used in certified healthcare settings.

What is a mechanism, and why does it matter?

A mechanism is an explanation of how a substance may affect cells or biological processes. Ketamine can block NMDA receptors involved in glutamate signaling. Identifying a receptor target does not prove benefit for every condition involving that brain system.

What does neuroplasticity mean here?

Neuroplasticity refers to changes in brain function and connections. NIH-supported laboratory work has investigated ketamine-related changes in neuronal connections in mice. Such findings can generate hypotheses for clinical studies, but they cannot demonstrate trauma recovery in a person or validate a compounded at-home formulation.

Terms such as BDNF or AMPA may appear in scientific papers, but a list of pathways is not a patient outcome. Claims that ketamine switches off fear, erases traumatic memories, or permanently strengthens emotional resilience go beyond what a mechanism alone can show.

Clinical studies must answer a different question

To evaluate a treatment, researchers need to measure meaningful outcomes in people, compare results appropriately, and assess harms and durability. The medication, route, dose, population, and setting must be clear. Studies of intravenous ketamine cannot be treated as proof for compounded nasal spray use at home. For clinical context, read our overview of ketamine PTSD research and guideline recommendations.

How can you use this information?

• Ask whether a claim comes from an animal experiment or a human treatment trial.
• Ask whether the study measured PTSD symptoms, depression, or a biological marker.
• Discuss recommended trauma-focused psychotherapy and medication options.
• If depression is also present, ask for separate goals for each condition.

Do not use the intensity of a drug experience as evidence that a brain mechanism is producing recovery. Tell your clinician about both your daily functioning and any distressing effects. Avoid changing medication or abandoning other care based on an appealing scientific explanation.

Risks and the treatment setting

Ketamine can cause sedation, dissociation, impaired thinking or coordination, increased blood pressure, and slowed breathing. Other concerns include abuse or misuse, worsening psychiatric symptoms, and urinary or bladder problems. A prescription or lower dose does not eliminate these risks.

At home, a healthcare professional is not onsite to monitor you or respond immediately to an adverse reaction. Virtual follow-up does not provide the same monitoring as an onsite team. Discuss whether the setting is appropriate, your medication interactions, and an emergency plan before treatment.

Discuss your questions with a clinician

Bliss Mist Rx LLC provides telehealth services and does not compound or manufacture medications. If treatment is prescribed, an independent, appropriately licensed compounding pharmacy dispenses the medication. A consultation does not guarantee a prescription; applicable prescribing and compounding requirements must be met.

Book a Free Virtual Appointment or Follow-Up to review your questions, alternatives, and next steps. This article provides general education and does not replace individualized medical advice.

Further reading: VA/DoD: PTSD guideline; Research on ketamine and NMDA receptors; NIH: laboratory research in mice; FDA: compounded-drug risks.